- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To demonstrate superiority in the overall survival (OS) of patients with progressive mCRPC treated with sunitinib plus prednisone (SP) versus placebo plus prednisone (PP) after failure of a docetaxel-based chemotherapy regimen.
Critère d'inclusion
- Progressive metastatic castration-resistant prostate cancer after failure of a Docetaxel-based chemotherapy regimen